Metagenomi Therapeutics, Inc. (MGX)
$1.20-$0.01 (-0.83%) Today
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 7,179 | $9K |
| Grant or award | 4 | 80,400 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from Dec 6, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Laurence Reid | Grant or award | Stock Option (Right to Buy) | 17,400 | $0.00 | - | |
| Willard H. Dere | Grant or award | Stock Option (Right to Buy) | 21,000 | $0.00 | - | |
 Eric Bjerkholt | Grant or award | Stock Option (Right to Buy) | 21,000 | $0.00 | - | |
| Juergen Eckhardt | Grant or award | Stock Option (Right to Buy) | 21,000 | $0.00 | - | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 2,884 | $1.30 | $4K | |
| Jian Irish - Officer | Open-market sale | Common Stock | 3,737 | $1.30 | $5K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 558 | $1.30 | $725 | |
| Jian Irish - Officer | Grant or award | Common Stock | 46,000 | $0.00 | - | |
| Jian Irish - Officer | Grant or award | Stock Option (Right to Buy) | 276,000 | $0.00 | - | |
| Matthew Wein - Officer | Grant or award | Common Stock | 11,000 | $0.00 | - | |
| Matthew Wein - Officer | Grant or award | Stock Option (Right to Buy) | 68,000 | $0.00 | - | |
| Pamela Wapnick - Officer | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Pamela Wapnick - Officer | Grant or award | Stock Option (Right to Buy) | 144,000 | $0.00 | - | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,581 | $1.60 | $3K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 482 | $1.60 | $771 | |
| Jian Irish - Officer | Open-market sale | Common Stock | 1,607 | $1.60 | $3K | |
| Jian Irish - Officer | Gift | Common Stock | 228,462 | $0.00 | - | |
| Brian C. Thomas | Open-market sale | Common Stock | 3,830 | $1.77 | $7K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 199 | $1.77 | $353 | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,576 | $1.77 | $3K | |
| Jian Irish - Officer | Open-market sale | Common Stock | 1,602 | $1.77 | $3K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 199 | $1.81 | $360 | |
| Matthew Wein - Officer | Grant or award | Common Stock | 96,000 | $1.60 | $154K | |
| Brian C. Thomas | Open-market sale | Common Stock | 2,701 | $1.81 | $5K | |
| Jian Irish - Officer | Open-market sale | Common Stock | 1,602 | $1.81 | $3K | |
| Jian Irish - Officer | Grant or award | Common Stock | 37,500 | $1.60 | $60K | |
| Jian Irish - Officer | Grant or award | Common Stock | 211,000 | $1.60 | $338K | |
| Jian Irish - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,576 | $1.81 | $3K | |
| Pamela Wapnick - Officer | Grant or award | Common Stock | 120,000 | $1.60 | $192K | |
| Laurence Reid | Grant or award | Stock Option (Right to Buy) | 42,000 | $0.00 | - | |
| Eric Bjerkholt | Grant or award | Stock Option (Right to Buy) | 8,572 | $0.00 | - | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,559 | $1.86 | $3K |
Metagenomi Therapeutics, Inc. (MGX) had 7 insider filings in the last 90 days, with the most recent on 2026-06-11. The full record for MGX runs to 24 Form 4 filings, the earliest from 2024-12-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MGX were filed in the last 90 days.
3 insider sales of MGX were filed in the last 90 days, totaling $9K.
This page tracks MGX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MGX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
